View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
  2. Company News
March 8, 2019updated 12 Jul 2022 1:08pm

Zynerba initiates Phase II CBD gel trial for autism

Zynerba Pharmaceuticals has initiated a Phase II clinical trial of its cannabinoid (CBD) gel Zygel (ZYN002) for the treatment of children and adolescents with autism spectrum disorder (ASD).

Zynerba Pharmaceuticals has initiated a Phase II clinical trial of its cannabinoid (CBD) gel Zygel (ZYN002) for the treatment of children and adolescents with autism spectrum disorder (ASD).

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Zygel is a pharmaceutically-manufactured CBD available as a permeation-enhanced clear gel formulation. It is intended for controlled, transdermal drug delivery into the bloodstream.

Prior studies indicate that autism could be related to a disruption in the endocannabinoid (EC) system. Other research suggests CBD may modify the EC system and improve some core social and behavioural symptoms associated with autism.

The open-label, multi-dose Phase II BRIGHT trial will investigate the safety, tolerability and efficacy of Zygel in around 36 ASD patients aged four to 17.

“Though there has been an accelerating rate of diagnosis, to date there are only two FDA approved products indicated for the treatment of ASD symptoms.”

Participants will be administered with weight-based initial daily doses of 250mg or 500mg.

The efficacy assessments will be conducted using the Aberrant Behavior Checklist, Parent Rated Anxiety Scale – Autism Spectrum Disorder, Autism Impact Measure and Clinical Global Impression – Severity and Improvement.

Top-line results from the BRIGHT trial are expected to be available in the first half of next year.

Zynerba Pharmaceuticals chairman and CEO Armando Anido said: “Though there has been an accelerating rate of diagnosis, to date there are only two FDA approved products indicated for the treatment of ASD symptoms. Both have significant side effect profiles, and neither have been approved to address the key symptoms of social impairment and anxiety.

“We are excited to initiate the BRIGHT trial evaluating the role of Zygel in ASD and are hopeful that Zygel may improve some of the core social and behavioural symptoms of ASD.”

The company started a pivotal trial of ZYN002 in patients with Fragile X syndrome (FXS) in July last year.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena